160 related articles for article (PubMed ID: 37728693)
1. BRCAness of brain lesions reflects a worse outcome for patients with metastatic breast cancer.
Ishizuka Y; Horimoto Y; Eguchi H; Murakami F; Nakai K; Onagi H; Hayashi T; Ishikawa T; Arai M; Watanabe J
Breast Cancer Res Treat; 2024 Jan; 203(1):49-55. PubMed ID: 37728693
[TBL] [Abstract][Full Text] [Related]
2. BRCAness as a prognostic indicator in patients with early breast cancer.
Liu L; Matsunaga Y; Tsurutani J; Akashi-Tanaka S; Masuda H; Ide Y; Hashimoto R; Inuzuka M; Watanabe C; Taruno K; Sawada T; Okuyama H; Ata A; Kuwayama T; Nakayama S; Tonouchi Y; Nakamura S
Sci Rep; 2020 Dec; 10(1):21173. PubMed ID: 33273622
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the BRCAness phenotype and its correlations with clinicopathological features in triple-negative breast cancers.
Tian T; Shan L; Yang W; Zhou X; Shui R
Hum Pathol; 2019 Feb; 84():231-238. PubMed ID: 30339969
[TBL] [Abstract][Full Text] [Related]
4. The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
Hjortkjær M; Malik Aagaard Jørgensen M; Waldstrøm M; Ørnskov D; Søgaard-Andersen E; Jakobsen A; Dahl-Steffensen K
Int J Gynecol Cancer; 2019 Jan; 29(1):166-173. PubMed ID: 30640700
[TBL] [Abstract][Full Text] [Related]
5. BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Tanino H; Kosaka Y; Nishimiya H; Tanaka Y; Minatani N; Kikuchi M; Shida A; Waraya M; Katoh H; Enomoto T; Sengoku N; Kajita S; Hoffman RM; Watanabe M
PLoS One; 2016; 11(12):e0165721. PubMed ID: 27935989
[TBL] [Abstract][Full Text] [Related]
6. Determination of BRCAness Phenotype in Breast Tumors for the Appointment of Neoadjuvant Chemotherapy Based on Platinum and Taxanes.
Tsyganov MM; Ibragimova MK; Garbukov EY; Bragina OD; Karchevskaya AA; Usynin EA; Litvyakov NV
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613648
[TBL] [Abstract][Full Text] [Related]
7. Relationship of immunohistochemistry, copy number aberrations and epigenetic disorders with BRCAness pattern in hereditary and sporadic breast cancer.
Murria Estal R; Palanca Suela S; de Juan Jiménez I; Alenda Gonzalez C; Egoavil Rojas C; García-Casado Z; López Guerrero JA; Juan Fita MJ; Sánchez Heras AB; Segura Huerta Á; Santaballa Bertrán A; Chirivella González I; Llop García M; Pérez Simó G; Barragán González E; Bolufer Gilabert P
Fam Cancer; 2016 Apr; 15(2):193-200. PubMed ID: 26723934
[TBL] [Abstract][Full Text] [Related]
8. Pathogenicity assessment of variants for breast cancer susceptibility genes based on BRCAness of tumor sample.
Yoshida R; Hagio T; Kaneyasu T; Gotoh O; Osako T; Tanaka N; Amino S; Yaguchi N; Nakashima E; Kitagawa D; Ueno T; Ohno S; Nakajima T; Nakamura S; Miki Y; Hirota T; Takahashi S; Matsuura M; Noda T; Mori S
Cancer Sci; 2021 Mar; 112(3):1310-1319. PubMed ID: 33421217
[TBL] [Abstract][Full Text] [Related]
9. Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness.
Lips EH; Laddach N; Savola SP; Vollebergh MA; Oonk AM; Imholz AL; Wessels LF; Wesseling J; Nederlof PM; Rodenhuis S
Breast Cancer Res; 2011 Oct; 13(5):R107. PubMed ID: 22032731
[TBL] [Abstract][Full Text] [Related]
10. Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.
Gross E; van Tinteren H; Li Z; Raab S; Meul C; Avril S; Laddach N; Aubele M; Propping C; Gkazepis A; Schmitt M; Meindl A; Nederlof PM; Kiechle M; Lips EH
BMC Cancer; 2016 Oct; 16(1):811. PubMed ID: 27756336
[TBL] [Abstract][Full Text] [Related]
11. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
[TBL] [Abstract][Full Text] [Related]
12. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S
BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626
[TBL] [Abstract][Full Text] [Related]
13. Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.
Hodgson D; Lai Z; Dearden S; Barrett JC; Harrington EA; Timms K; Lanchbury J; Wu W; Allen A; Senkus E; Domchek SM; Robson M
Ann Oncol; 2021 Dec; 32(12):1582-1589. PubMed ID: 34500047
[TBL] [Abstract][Full Text] [Related]
14. Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests.
Meijer TG; Nguyen L; Van Hoeck A; Sieuwerts AM; Verkaik NS; Ladan MM; Ruigrok-Ritstier K; van Deurzen CHM; van de Werken HJG; Lips EH; Linn SC; Memari Y; Davies H; Nik-Zainal S; Kanaar R; Martens JWM; Cuppen E; Jager A; van Gent DC
Oncogene; 2022 Jun; 41(26):3498-3506. PubMed ID: 35662281
[TBL] [Abstract][Full Text] [Related]
15. BRCAness, Homologous Recombination Deficiencies, and Synthetic Lethality.
Murai J; Pommier Y
Cancer Res; 2023 Apr; 83(8):1173-1174. PubMed ID: 37057596
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of CXCL1 and LY9 contributes to BRCAness in ovarian cancer and mediates response to PARPi and immune checkpoint blockade.
Chen T; Yu T; Zhuang S; Geng Y; Xue J; Wang J; Ai L; Chen B; Zhao Z; Li Y; Wang J; Liang H; Xu Y; Gu Y
Br J Cancer; 2022 Sep; 127(5):916-926. PubMed ID: 35618786
[TBL] [Abstract][Full Text] [Related]
17. Investigation of BRCAness associated miRNA-gene axes in breast cancer: cell-free miR-182-5p as a potential expression signature of BRCAness.
Darbeheshti F; Kadkhoda S; Keshavarz-Fathi M; Razi S; Bahramy A; Mansoori Y; Rezaei N
BMC Cancer; 2022 Jun; 22(1):668. PubMed ID: 35715772
[TBL] [Abstract][Full Text] [Related]
18. Analysis of BRCAness with multiplex ligation-dependent probe amplification using formalin-fixed and paraffin-embedded pancreatic ductal adenocarcinoma tissue obtained via endoscopic ultrasound-guided fine-needle aspiration biopsy.
Okuwaki K; Masutani H; Imaizumi H; Yoshida T; Kida M; Iwai T; Yamauchi H; Tadehara M; Adachi K; Watanabe M; Kurosu T; Koizumi W
Pancreatology; 2019 Apr; 19(3):419-423. PubMed ID: 30819577
[TBL] [Abstract][Full Text] [Related]
19. BRCAness Combined With a Family History of Cancer Is Associated With a Poor Prognosis for Breast Cancer Patients With a High Risk of BRCA Mutations.
Mori H; Kubo M; Kai M; Velasquez VV; Kurata K; Yamada M; Okido M; Kuroki S; Oda Y; Nakamura M
Clin Breast Cancer; 2018 Oct; 18(5):e1217-e1227. PubMed ID: 29941390
[TBL] [Abstract][Full Text] [Related]
20. Non-BRCA1/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAness.
Andersen LVB; Larsen MJ; Davies H; Degasperi A; Nielsen HR; Jensen LA; Kroeldrup L; Gerdes AM; Lænkholm AV; Kruse TA; Nik-Zainal S; Thomassen M
Breast Cancer Res; 2023 Jun; 25(1):69. PubMed ID: 37316882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]